Compare Wayfair Inc (W) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wayfair Inc vs GeneDx Holdings Corp — how do they compare? Wayfair Inc trades at $100.12 (market cap $13.69B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Wayfair Inc is far larger — about 5.3× GeneDx Holdings Corp's market cap, and Wayfair Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| W | WGS | |
|---|---|---|
Market Cap | $13.69B | $2.56B |
Sector | Consumer Cyclical | Technology |
52-Week High | $119.05 | $167.51 |
52-Week Low | $57.40 | $34.51 |
Enterprise Value | $16.03B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $99.96, up 0.53% today, with a bullish technical signal supported by moving averages. The stock shows strong revenue growth of 7.5% year-over-year in Q2 2026 and has beaten earnings estimates in two of the last three quarters. Recent positive sentiment follows the company's 10th store announcement and a golden cross technical pattern. However, the company continues to report net losses with a -2.49% net income margin and carries significant debt with a 95.11% debt-to-asset ratio.
Wayfair presents a mixed investment case with strong revenue momentum and market share gains offset by persistent profitability challenges. The consensus price target of $125.14 suggests 25% upside potential, supported by 53.57% analyst buy ratings. Key risks include ongoing net losses, high leverage, and consumer spending sensitivity. The stock's technical strength and expansion initiatives provide catalysts, but profitability improvement remains critical for sustained upside.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
